# Maraviroc to Augment Rehabilitation Outcomes After Stroke

> **NCT03172026** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of California, Los Angeles** · enrollment: 2 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Maraviroc 300 mg
- **BEHAVIORAL:** Rehabilitation therapy
- **DRUG:** Placebo 300 mg

## Key facts

- **NCT ID:** NCT03172026
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Poor recruitment for each site, partly related to Covid epidemic.
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172026, "Maraviroc to Augment Rehabilitation Outcomes After Stroke". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03172026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*